IF and IHC experiments demonstrated a significant increase in the expression of phosphorylated TBK1 (p-TBK1), phosphorylated IRF3 (p-IRF3) and IFN-β within the tumor tissue after combination therapy (Fig. 7f, g). The gene discussed is TBK1; the disease is neoplasm.